Recently, Integrated DNA Technologies (hereinafter referred to as “IDT”), a world-leading genomics solutions provider under Danaher, announced the establishment of IDT China to better cultivate and serve the Chinese market. Meanwhile, Li Chen has been appointed as General Manager of IDT China. Having previously worked at multiple multinational corporations and consulting firms, her extensive professional experience will help IDT further expand its presence in the Chinese market. 
IDT Icon
Danaher LogoInnovative Products and Services Power China’s Precision Medicine
IDT is part of the Danaher Life Sciences platform. As a company with over 30 years of history, IDT has been dedicated to developing high-quality genomics and custom nucleic acid products for the life sciences sector, which are widely used in various fields including medical diagnostics, drug development, scientific research, and agricultural breeding. In the field of genomics, IDT has developed multiple breakthrough patented technologies, such as next-generation sequencing (NGS), CRISPR genome editing, synthetic biology, and RNA interference. These technologies have been utilized by scientists to study various cancers, as well as genetic and infectious diseases. In particular, IDT’s comprehensive NGS solutions can be applied throughout the entire precision medicine workflow, from discovery to diagnosis, ensuring the confidence and reliability required for personalized medicine.Furthermore, IDT is a widely recognized leader in the custom nucleic acid production industry, boasting extensive expertise in manufacturing custom oligonucleotides for molecular biology research. High-quality oligonucleotides are IDT’s core products that distinguish it in the market, with daily production volume of this product alone exceeding 70,000 units.In recent years, driven by a combination of talent, policy, and technological advancements, China has achieved remarkable progress in precision medicine and molecular biology. However, the long-term development of these fields requires further support from advanced technologies and high-quality products. Integrated DNA Technologies (IDT)’s pioneering next-generation sequencing (NGS) products, such as the xGen series, along with its unique oligonucleotide offerings, can provide strong impetus for personalized medicine in China’s life sciences sector and for molecular biology-based disease diagnostics.Trey Martin, President of IDT, stated, “The establishment of IDT China enables our team to better provide localized support in this region and carry out important research projects. China has made remarkable progress in the field of life science research and has become a leader in the development of new technologies for translational medicine and personalized medicine. We look forward to contributing to the advancement of these developments.”The Chinese Market Becomes One of IDT's Key Strategic MarketsLeveraging years of accumulated expertise in high-quality development technologies within genomics and custom oligonucleotides, IDT is continuously expanding its global footprint to better serve healthcare and research institutions worldwide. As one of IDT’s key strategic markets, China holds immense potential in leading the world’s exploration of personalized medicine. To this end, IDT is actively introducing advanced technologies and products into China to foster the development of the life sciences sector in the country.In response, Li Bing, President of Danaher Life Sciences China, stated: “Since the establishment of the Danaher Life Sciences platform in China, we have been putting our platform mission—‘Sharing Global Science and Technology for Universal Health’—into practice through concrete actions under this new ‘China Model.’ By focusing on biopharmaceuticals and precision medicine as our key strategic priorities and closely aligning with local customer needs, we are driving the in-depth development of the life sciences sector.”As part of the Danaher Life Sciences platform, the establishment of a local entity by Integrated DNA Technologies (IDT) in China marks a significant and positive milestone in IDT’s commitment to advancing the life sciences sector in the country. The founding of IDT China will enable the company to gain deeper insights into customer needs, delivering high-quality customized services and after-sales support to meet individualized requirements, thereby securing greater competitive advantages for future growth.Chen Li, General Manager of IDT China, stated, “As one of the youngest operating companies within Danaher’s Life Sciences platform in China, IDT is full of vitality. Looking ahead, IDT China will continue to deliver more accessible and rapid innovative next-generation sequencing (NGS) products and technologies. Leveraging our superior quality standards and product performance, we aim to empower medical researchers to achieve new breakthroughs, support them in developing more precise and effective diagnostic and treatment solutions, help our Chinese partners further enhance the competitive advantage of their clinical diagnostic products, and contribute robustly to the advancement of precision medicine in China.” | 
